Alzheimer’s Disease Target: β-amyloid Protein
|
Antigen
|
Species
|
Intrabody
|
Experimental Phase
|
Reference(s)
|
Aβ1–42 |
scFv |
scFvAβIB
|
Preclinical in mice |
[8] |
Aβ |
scFv |
Aβ-scFv |
Preclinical in mice |
[9] |
Parkinson’s Disease Target: α-synuclein Protein
|
Antigen
|
Species
|
Intrabody
|
Experimental Phase
|
Reference(s)
|
Oligomeric α-synuclein |
Human scFv |
D5 |
Preclinical in mice |
[10,11,12,13] |
Oligomeric α-synuclein |
Human scFv |
10H |
Preclinical in mice |
[10,12,14] |
Pan-specific α-synuclein |
Human scFv |
D10 |
Preclinical in mice |
[10,12,15] |
Hydrophobic non-amyloid component (NAC) of α-synuclein, AA53–95 |
Human nanobody (VH) |
VH14 (NAC14) |
Preclinical in rats |
[10,16,17] |
α-synuclein AA53–87 |
Human scFv |
NAC32 |
In vitro in cell culture |
[17] |
Fibrillar α-synuclein |
Human scFv |
6E |
In vitro in cell culture |
[11,18] |
α-synuclein, AA118–131 |
Camelid nanobody (VHH) |
Nbsyn2 |
In vitro in cell culture |
[16,19] |
α-synuclein, AA137-140 |
Camelid nanobody (VHH) |
Nbsyn87 |
Preclinical in rats |
[16,19,20] |
Huntington’s Disease Target: Huntingtin (HTT) Protein
|
Antigen
|
Species
|
Intrabody
|
Experimental Phase
|
Reference(s)
|
HTT-N17 (PolyQ N-term AA1-17) |
Human scFv |
scFvC4 |
Preclinical in mice |
[11,21,22,23,24,25,26,27,28,29,30] |
HTT-N20 (PolyQ N-term, AA1-20) |
Human VL |
VL12.3 |
Preclinical in mice |
[22,31,32,33,34,35] |
HTT-polyQ |
Mouse scFv |
MW1 |
In vitro in cell culture |
[36,37] |
HTT-polyQ |
Mouse scFv |
MW2 |
In vitro in cell culture |
[36,37] |
HTT-PRR |
Mouse scFv |
MW7 |
Ex vivo in brain tissue |
[33,36,37] |
HTT-PRR |
Human VL |
Happ1 |
Preclinical in mice |
[33,34] |
HTT-PRR |
Human VL |
Happ3 |
Ex vivo in brain tissue |
[33] |
HTT-Exon1 |
Mouse scFv |
EM48 |
Preclinical in mice |
[38] |
HTT-PRR |
Human scFv |
INT41 |
Preclinical in mice |
[39] |
Fibrillar mHTT |
Human scFv |
6E |
In vitro in cell culture |
[18,21] |
Amyotrophic Lateral Sclerosis (ALS) Disease Target: SOD1 Protein
|
Antigen
|
Species
|
Intrabody
|
Experimental Phase
|
Reference(s)
|
SOD1 |
Human scFv |
B1 |
Preclinical in mice |
[40,41] |
SOD1 |
Human scFv |
B12 |
Preclinical in mice |
[40,41] |
G93A human SOD1 |
Mouse scFv |
D3H5 |
Preclinical in mice |
[42] |
Prion Disorder Target: Prion Protein (PrP)
|
Antigen
|
Species
|
Intrabody
|
Experimental Phase
|
Reference(s)
|
Cellular PrP |
Mouse scFv |
8H4 |
Preclinical in mice |
[43,44] |
Cellular PrP |
Mouse scFv |
8F9 |
In vitro in cell culture |
[43] |
Cellular PrP |
Camelid nanobody (VHH) |
Nb_PrP_01 |
In vitro in crystallography studies |
[45,46] |
Cellular PrP AA123–125, 164–170, and 174–185 |
Camelid nanobody (VHH) |
Nb484 |
In vitro in crystallography studies |
[46] |